Blood advances

Macrophage Activation Syndrome-Like Manifestations (MAS-L) Following BCMA-directed CAR T-cells in Multiple Myeloma.

Blood advances

Kennedy VE, Wong C, Huang CY, Kambhampati S, Wolf JL, Martin TG, Shah N, Wong SW

VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis.

Blood advances

Kennedy VE, Wong CC, Hong JM, Peng TA, Brondfield S, Reilly LM, Cornett P, Leavitt AD

Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy.

Blood advances

Kambhampati S, Sheng Y, Huang CY, Bylsma SA, Lo M, Kennedy VE, Natsuhara K, Martin T, Wolf JL, Shah N, Wong SW

IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS.

Blood advances

Lin H, Scull BP, Goldberg BR, Abhyankar HA, Eckstein OE, Zinn DJ, Lubega J, Agrusa J, El Mallawaney N, Gulati N, Forbes L, Chinn I, Chakraborty R, Velasquez J, Goldman J, Bashir D, Lam F, Muscal E, Henry MM, Greenberg JN, Ladisch S, Hermiston ML, Meyer LK, Jeng M, Naqvi A, McClain K, Nguyen T, Wong H, Man TK, Jordan MB, Allen CE

B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations.

Blood advances

Six KA, Gerdemann U, Brown AL, Place AE, Cantor AB, Kutny MA, Avagyan S

Single-cell ATAC-seq reveals GATA2-dependent priming defect in myeloid and a maturation bottleneck in lymphoid lineages.

Blood advances

Avagyan S, Weber MC, Ma S, Prasad M, Mannherz WP, Yang S, Buenrostro JD, Zon LI

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib.

Blood advances

Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, Levis MJ, Perl A, Huang BJ, Smith CC

Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation.

Blood advances

Maglitto A, Mariani SA, de Pater E, Rodriguez-Seoane C, Vink CS, Piao X, Lukke ML, Dzierzak E

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.

Blood advances

Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

Blood advances

Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC

Pages